Unichem Laboratories Ltd
NSE: UNICHEMLAB BSE: 506690
₹373
(-0.08%)
Sat, 23 May 2026, 06:42 pm
Market Cap26.23B
PE Ratio8.92
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1962
- The Company was incorporated on 22nd August, at Bombay.
- The Company manufactures pharmaceutical products and chemicals on behalf of Uni-U.C.B.(India) Pvt.Ltd., associates of the reputed UCB of Brussels, Belgium.
- Government approved the scheme to manufacture dextran and iron dextran cycoside in collaboration with Roshkilde Medical Company of Denmark.
- Government also approved the Collaboration Scheme with Shofu Dental Mfg.Co.Ltd., Japan, for the manufacture of dental products.
- The Company was formed to take over as a going concern the proprietary business carried on since 1944, at Bombay, by Shri A V Mody as manufacturing chemist and dealer in pharmaceuticals and medicines, under the name and style of 'Unichem Laboratories'.
1983
- The Upjohn division was established, the name was changed to UNISEARCH division with effect from 1st October, 1987.
1992
- Unichem Exports Limited ceased to be a subsidiary of the company from 17th November.
1993
- The Company introduced a new antibiotic in the market, and incurred substantial cost on the new launch.
1994
- The Company made an Issue of Equity Shares to the shareholders, promoters and employees as a result of which the Equity share Capital has increased to Rs.199.12 lacs.
1995
- The Pharma Division extended its products range by launching two new molecules and one additional formulation in the market.
- 5,59,900 No. of Equity Warrants were allotted to the Promoters/Promoter Group.
1998
- The Company has launched three new products in three different therapeutic areas i.e. Cardiovascular, Anti Inflammatory and Anti oxidant under the brand names CORVADIL-A, PRONIM and PRO-RIDAGE.
- The company has a technical collaboration with Shofu Dental Manufacturing Co, Japan and Roshkilde Medical Co, Denmark.
- The Company has launched three new products in three different therapeutic areas viz., Satin a cholesterol reducer in the area of cardiovascular therapeutic segment; Domadol in the post operative pain management segment and Zonep in the psychiatry segment.
- The company recently commissioned a Rs 20-crore manufacturing facility at Bardez in Goa, specially designed to meet stringent standards in export markets.
1999
- The Company's new Division mainly catering to Women's Healthcare called FOREVA was launched on 1st April.
- The Company has launched eight new products, Losar, Serta, Biclar, Zisper, M-cam, Flospar, Lanpro, Anticox 3.
- Unichem Laboratories, a leading pharmaceutical company, has launched M-Cam', a non-steroidal anti-inflammatory drug (NSAID) for the treatment or arthritis.
- The company has recently commissioned its multi-purpose facility at Roha in Maharashtra to manufacture a range of bulk drugs scheduled to go off patent in advanced markets by 2000.
- The company has tied up with Aptech and NIIT to reach a majority of the nearly 3,000 cardiologists and over 20,000 physician MDs in the country.
2000
- Unichem Laboratories has entered into a strategic alliance with the Korean Green Cross Corporation to market Urokinase.
- The Company has introduced Celib for management of arthritis.
- Unichem Laboratories has launched Zulu, the first muscle relaxant containing nimesulide and tizanidine.
- The Foreva, the Women's healthcare division of the company has acquired the marketing and distribution rights for Partobulin (Anti-D Immunoglobulin) in India from Baxter Healthcare.
- The Company will launch its own version of Pfizer's impotence pill Viagra under the brand name Erix.
2001
- Foreva, the women's healthcare division of Unichem Laboratories, has entered into a technical tie-up with the US-based Protein Technologies International Inc, a DuPont division, for developing a soya protein supplement for women called Nutreva.
2002
- Enters into Joint Venture with the former Directors of the Bioglan group in Ireland.
- Bharat Bio signs marketing alliance with the company to market hepatitis-B, recombinant.
- Ind-Swift ties up with the company for Co-marketing pact to co-market finished dosages of its anti-depressant drug citalopram
2003
- Registered a net profit increase by around 10.6% in the I quarter at Rs.9.4crs for the same period last year.
- Enters into an agreement for the sale of its Animal Healthcare Division to M/s Tetragon Chemie Ltd.
- Appoints Mr Prafful D Sheth as the Director of the company.
- Unichem Laboratories Ltd, a Mumbai based Rs 475-crore pharmaceutical company, has received ISO 9001 & 14001 certificates
2006
- Unichem Laboratories enters into agreement with PLIVA inc, USA
2009
- Unichem Laboratories Ltd has appointed Mr. Harcharan Singh as Chief Executive - Pharma with effect from March 24, 2009.
2010
- Unichem Laboratories Ltd has received approval from US Food & Drug Administration (U.S. FDA) for Hydrochlorothiazide Capsules in the strengths of 12.5 mg
- Unichem Laboratories Ltd strengthened 6.38% to close at Rs 381.15 as the company has received EU GMP certificate from IRISH Medicines Board for the 12 API's manufactured at Company's Roha plant.
- Company has splits its Face value of Shares from Rs 5 to Rs 2
2011
- Unichem Laboratories Ltd has received approval from US Food & Drug Administration (FDA) for Divalproex Sodium Delayed Release Tablets USP 125mg, 250mg and 500mg (Valproic -Acid Activity).
2012
- Mr. Bhagwat S. Dhingra has been appointed as Chief Executive - Domestic Pharma
- Unichem Laboratories receives ANDA tentative approval from USFDA for IRBESARTAN TABLETS
- Unichem gets tentative nod from USFDA for dementia tablets.
2013
- Unichem Laboratories receives ANDA approval from USFDA for Amlodipine Besylate Tablets
- Unichem Laboratories has recommended Dividend of Rs. 4.50 (225%) per equity share of Rs. 2/- each.
2014
- Unichem Laboratories receives ANDA approval from USFDA for Metronidazole USP Tablets
- Unichem Laboratories has recommended Final Dividend of Rs. 4/- (200%) per equity share of Rs. 2/- each.
2015
- Unichem bags ANDA approval for Montelukast Sodium tablets
- Acquired API manufacturing unit at Kolhapur
- Commissioned expanded capacities at Goa plant
2017
- Divested domestic formulation business to Torrent Pharma
2019
- Strategic investment in Hyderabad based Optimus Drugs Pvt Ltd. & Optrix Laboratories Pvt Ltd.
- New plant site acquired in Goa
- Product facility expansions in Ghaziabad and Pithampur
2020
- Unichem Laboratories gets USFDA nod to market generic version of tolterodine tartrate tablets.
2021
- Unichem Laboratories receives USFDA approval for Aripiraprazole tablets.
- Unichem Laboratories receives USFDA approval for Zonisamide Capsules.
- Unichem Laboratories gets USFDA nod for plaque psoriasis treatment drug.
- New Oral Solid Dosage manufacturing facility commissioned at Goa Plant II.
2022
- Unichem Laboratories receives ANDA approval for Extended Phenytoin Sodium Capsules.
- Unichem Labs gets US FDA nod for Schizophrenia drug.
2023
- Ipca Laboratories Limited acquires 52.67% of the paid-up share capital of Unichem.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800